
Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software
Betsy Goodfellow | January 17, 2024 | News story | Business Services |ย ย Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemiaย
Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the hospital will be able to use the Qlucore Insights software in order to improve the diagnosis of acute lymphoblastic leukaemia (ALL) in children.
This agreement marks an expansion for Qlucore, as this is the companyโs first precision diagnostics order in Sweden, despite having existing customers in both Denmark and Italy.
The company aims to โhelp customers develop analyses that contribute to a more accurate diagnosis, enabling clinicians to make more informed treatment choices,โ according to the press release. This is especially in ALL, as this is the most common form of childhood leukaemia as it impacts 90% of children who are diagnosed with leukaemia.
Carl-Johan Ivarsson, chief executive officer of Qlucore, commented: โOur solutions will facilitate and enable improved diagnostics of cancer; in this case, acute lymphoblastic leukemia (ALL). The goal is to make it easier for the doctor to make a diagnosis and decide how the disease should be treated, and for the patients to receive more precise treatment.โ
Betsy Goodfellow
Related Content

ViroCell and UCL launch trial to treat childhood leukaemia relapse
ViroCell Biologics has manufactured a GMP-grade lentiviral vector for a University College London (UCL) clinical …

Eli Lillyโs Jaypirca approved in US for leukaemia and lymphoma treatment
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca …

Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib
Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT …






